← Back to guidelines
Urology19 papers

Regressed malignant testicular tumor

Last edited: 4/15/2026

Overview

Testicular tumors in prepubertal boys are rare, accounting for 1-2% of all solid pediatric tumors, often benign, and differing histologically from those in older individuals 1.

Diagnosis

  • Clinical Presentation: Painless scrotal mass 1.
  • Imaging: High-resolution ultrasound for evaluation with near 100% detection rate 1.
  • Tumor Markers: Alpha-fetoprotein (AFP) used, though age-dependent sensitivity 1.
  • Not Useful: Human chorionic gonadotropin (HCG) is not a reliable tumor marker in this population 1.
  • Management

  • Primary Approach: Partial orchiectomy recommended for tumors with favorable characteristics 1.
  • No Specific Drug Therapy Mentioned: No specific drug classes or doses detailed for regressed malignant tumors in prepubertal boys 1.
  • Special Populations

  • Pediatric Considerations: Tailored approach due to differences in tumor characteristics compared to older patients 1.
  • Key Recommendations

  • Perform high-resolution ultrasound for evaluation of testicular masses in prepubertal boys (Evidence: Strong) 1.
  • Utilize alpha-fetoprotein (AFP) as a tumor marker, considering its age-dependent sensitivity (Evidence: Moderate) 1.
  • Opt for partial orchiectomy as the primary surgical intervention for regressed malignant testicular tumors in prepubertal boys (Evidence: Expert opinion) 1.
  • References

    1 Stein R, Quaedackers J, Bhat NR, Dogan HS, Nijman RJM, Rawashdeh YF et al.. EAU-ESPU pediatric urology guidelines on testicular tumors in prepubertal boys. Journal of pediatric urology 2021. link

    Original source

    1. [1]
      EAU-ESPU pediatric urology guidelines on testicular tumors in prepubertal boys.Stein R, Quaedackers J, Bhat NR, Dogan HS, Nijman RJM, Rawashdeh YF et al. Journal of pediatric urology (2021)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG